Menu
Search
|

Menu

Close
X

Edge Therapeutics Inc EDGE.OQ (NASDAQ Stock Exchange Global Select Market)

13.95 USD
-- (--)
As of Feb 16
chart
Previous Close 13.95
Open --
Volume --
3m Avg Volume 23,537
Today’s High --
Today’s Low --
52 Week High 14.40
52 Week Low 7.44
Shares Outstanding (mil) 30.85
Market Capitalization (mil) 340.91
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-1.230
FY16
-1.345
FY15
-1.900
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
4.04
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
23.99
16.52
LT Debt to Equity (MRQ)
vs sector
20.32
12.22
Return on Investment (TTM)
vs sector
-43.75
14.43
Return on Equity (TTM)
vs sector
-48.11
16.13

EXECUTIVE LEADERSHIP

Sol Barer
Independent Chairman of the Board, Since 2013
Salary: --
Bonus: --
Brian Leuthner
President, Chief Executive Officer, Director, Since
Salary: $467,500.00
Bonus: --
Isaac Blech
Independent Vice Chairman of the Board, Since
Salary: --
Bonus: --
Andrew Saik
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Daniel Brennan
Chief Operating Officer, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

300 Connell Dr Ste 4000
BERKELEY HEIGHTS   NJ   07922-2817

Phone:

Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company's initial product candidates target rare, acute, life-threatening neurological and other conditions. The Company's product candidates utilize its programmable, biodegradable polymer-based development platform (the Precisa Platform), a delivery mechanism that seeks to enable targeted and sustained drug exposure and avoid the dose-limiting side effects associated with the current standards of care. The Company's product candidates include EG-1962 and EG-1964. EG-1962 is a polymer-based microsphere containing nimodipine suspended in a diluent of sodium hyaluronate was developed using its Precisa development platform to improve patient outcomes following aneurysmal subarachnoid hemorrhage (aSAH).

SPONSORED STORIES